Early cardiovascular vulnerability after acute exacerbation of COPD: a time-windowed systematic review and evidence map.
Junsong Xu, Qingyong Chen, Bingchen Zhang et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and evidence map examined cardiovascular events during and after exacerbations of COPD, asthma, or bronchiectasis, with COPD as the primary evidence base. It included observational studies and post hoc trial analyses; heterogeneity precluded a pooled meta-analysis. Of 110 extracted effect estimates, 101 concerned COPD and 57 fell within 30-day windows after harmonization. Early cardiovascular risk was consistently higher than later risk, particularly after severe or hospitalized COPD exacerbations, with the clearest vulnerability during the first month.
Key findings
- Of 110 extracted effect estimates, 101 related to COPD; 57 fell within 30-day windows after time-window harmonization.
- Early cardiovascular risk was consistently higher than later risk, especially after severe or hospitalized COPD exacerbations.
- Signals involved coronary events, ischemic stroke, heart failure, atrial fibrillation or arrhythmia, cardiovascular death, and composite severe cardiovascular outcomes.
- Evidence for cardiovascular events after asthma or bronchiectasis exacerbations was sparse and exploratory.
Why it matters
The review organizes evidence around when cardiovascular vulnerability may be greatest after a COPD exacerbation, rather than offering a single pooled risk estimate. Recognizing the first month—particularly after severe or hospitalized exacerbations—as a potential cardiopulmonary transition period may help frame respiratory recovery and follow-up while acknowledging that the evidence is heterogeneous.
What to keep in mind
Study designs, endpoints, severity definitions, comparators, and risk windows differed materially, preventing pooled meta-analysis. Evidence for asthma and bronchiectasis was sparse and exploratory.